This year's U.S. News & World Report list of top cancer hospitals includes MD Anderson Cancer Center, Memorial Sloan ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

Celcuity ( (CELC)) has shared an announcement. On July 28, 2025, Celcuity Inc. announced positive topline results from its Phase 3 VIKTORIA-1 clinical trial, which evaluated gedatolisib plus ...

US clinical-stage oncology focused biotech Celcuity saw its shares skyrocket 180% to $38.59 in early trading as it announced ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

Celcuity Inc. (CELC) stock surged about 221% on Monday morning after the company announced that its experimental combination ...

Celcuity said its Phase 3 clinical trial evaluating gedatolisib resulted in positive topline results. The clinical-stage biotechnology company's trial evaluated gedatolisib plus fulvestrant with and ...

Celcuity Inc. (NASDAQ: CELC) stock surged over 100% following the announcement of positive Phase 3 trial results for its breast cancer drug gedatolisib, which sho ...